Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 146

Similar articles for PubMed (Select 22318281)

1.

Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants.

Shui IM, Baggs J, Patel M, Parashar UD, Rett M, Belongia EA, Hambidge SJ, Glanz JM, Klein NP, Weintraub E.

JAMA. 2012 Feb 8;307(6):598-604. doi: 10.1001/jama.2012.97.

PMID:
22318281
2.

Intussusception risk after rotavirus vaccination in U.S. infants.

Yih WK, Lieu TA, Kulldorff M, Martin D, McMahill-Walraven CN, Platt R, Selvam N, Selvan M, Lee GM, Nguyen M.

N Engl J Med. 2014 Feb 6;370(6):503-12. doi: 10.1056/NEJMoa1303164. Epub 2014 Jan 14.

3.

Risk of intussusception after monovalent rotavirus vaccination.

Weintraub ES, Baggs J, Duffy J, Vellozzi C, Belongia EA, Irving S, Klein NP, Glanz JM, Jacobsen SJ, Naleway A, Jackson LA, DeStefano F.

N Engl J Med. 2014 Feb 6;370(6):513-9. doi: 10.1056/NEJMoa1311738. Epub 2014 Jan 14.

4.

Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine.

Loughlin J, Mast TC, Doherty MC, Wang FT, Wong J, Seeger JD.

Pediatr Infect Dis J. 2012 Mar;31(3):292-6. doi: 10.1097/INF.0b013e3182421390.

PMID:
22173146
5.

Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico.

Velázquez FR, Colindres RE, Grajales C, Hernández MT, Mercadillo MG, Torres FJ, Cervantes-Apolinar M, DeAntonio-Suarez R, Ortega-Barria E, Blum M, Breuer T, Verstraeten T.

Pediatr Infect Dis J. 2012 Jul;31(7):736-44. doi: 10.1097/INF.0b013e318253add3.

PMID:
22695189
6.

Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007.

Haber P, Patel M, Izurieta HS, Baggs J, Gargiullo P, Weintraub E, Cortese M, Braun MM, Belongia EA, Miller E, Ball R, Iskander J, Parashar UD.

Pediatrics. 2008 Jun;121(6):1206-12. doi: 10.1542/peds.2007-3793.

7.

Vaccines for preventing rotavirus diarrhoea: vaccines in use.

Soares-Weiser K, Maclehose H, Bergman H, Ben-Aharon I, Nagpal S, Goldberg E, Pitan F, Cunliffe N.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD008521. doi: 10.1002/14651858.CD008521.pub3. Review.

PMID:
23152260
8.

Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program.

Carlin JB, Macartney KK, Lee KJ, Quinn HE, Buttery J, Lopert R, Bines J, McIntyre PB.

Clin Infect Dis. 2013 Nov;57(10):1427-34. doi: 10.1093/cid/cit520. Epub 2013 Aug 26.

9.

Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States.

Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD.

Pediatr Infect Dis J. 2013 Mar;32(3):278-83. doi: 10.1097/INF.0b013e318275328f.

PMID:
23014356
10.

Intussusception after rotavirus vaccines reported to US VAERS, 2006-2012.

Haber P, Patel M, Pan Y, Baggs J, Haber M, Museru O, Yue X, Lewis P, Destefano F, Parashar UD.

Pediatrics. 2013 Jun;131(6):1042-9. doi: 10.1542/peds.2012-2554. Epub 2013 May 13.

11.

Trends in intussusception hospitalizations among US infants before and after implementation of the rotavirus vaccination program, 2000-2009.

Yen C, Tate JE, Steiner CA, Cortese MM, Patel MM, Parashar UD.

J Infect Dis. 2012 Jul 1;206(1):41-8. doi: 10.1093/infdis/jis314. Epub 2012 Apr 26.

12.

Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States.

Boom JA, Tate JE, Sahni LC, Rench MA, Hull JJ, Gentsch JR, Patel MM, Baker CJ, Parashar UD.

Pediatrics. 2010 Feb;125(2):e199-207. doi: 10.1542/peds.2009-1021. Epub 2010 Jan 18.

13.

Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States.

Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD.

Pediatrics. 2010 Feb;125(2):e208-13. doi: 10.1542/peds.2009-1246. Epub 2010 Jan 25.

14.

Potential intussusception risk versus benefits of rotavirus vaccination in the United States.

Desai R, Cortese MM, Meltzer MI, Shankar M, Tate JE, Yen C, Patel MM, Parashar UD.

Pediatr Infect Dis J. 2013 Jan;32(1):1-7. doi: 10.1097/INF.0b013e318270362c.

PMID:
22929172
15.

Vaccines for preventing rotavirus diarrhoea: vaccines in use.

Soares-Weiser K, Maclehose H, Bergman H, Ben-Aharon I, Nagpal S, Goldberg E, Pitan F, Cunliffe N.

Cochrane Database Syst Rev. 2012 Feb 15;2:CD008521. doi: 10.1002/14651858.CD008521.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;11:CD008521.

PMID:
22336845
16.

Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua.

Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, Gonzalez A, Malespin O, Amador JJ, Umaña J, Balmaseda A, Perez MC, Gentsch J, Kerin T, Hull J, Mijatovic S, Andrus J, Parashar U.

JAMA. 2009 Jun 3;301(21):2243-51. doi: 10.1001/jama.2009.756.

PMID:
19491186
17.

Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.

Laserson KF, Nyakundi D, Feikin DR, Nyambane G, Cook E, Oyieko J, Ojwando J, Rivers SB, Ciarlet M, Neuzil KM, Breiman RF.

Vaccine. 2012 Apr 27;30 Suppl 1:A61-70. doi: 10.1016/j.vaccine.2011.09.026.

PMID:
22520138
18.

Rotavirus live, oral, pentavalent vaccine.

Tom-Revzon C.

Clin Ther. 2007 Dec;29(12):2724-37. doi: 10.1016/j.clinthera.2007.12.018. Review.

PMID:
18201590
19.
20.

Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).

Dennehy PH, Vesikari T, Matson DO, Itzler RF, Dallas MJ, Goveia MG, DiNubile MJ, Heaton PM, Ciarlet M.

Hum Vaccin. 2011 May;7(5):563-8. Epub 2011 May 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk